Trials / Recruiting
RecruitingNCT05652920
Ori-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCC
A Phase Ib/II, Open-Label, Multi-Center Study to Investigate the Safety, PK, and Efficacy of Ori-C101 in Advanced Hepatocellular Carcinoma (HCC) Patients (BEACON)
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 105 (estimated)
- Sponsor
- OriCell Therapeutics Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase I, open-label, multi-center study to assess the safety, pharmacokinetics, and preliminary efficacy of GPC3-directed chimeric antigen receptor modified T cells injection (Ori-C101) in Advanced Hepatocellular Carcinoma(HCC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Ori-C101 | Hepatic arterial infusion |
Timeline
- Start date
- 2022-12-15
- Primary completion
- 2026-12-01
- Completion
- 2026-12-01
- First posted
- 2022-12-15
- Last updated
- 2024-04-03
Locations
7 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05652920. Inclusion in this directory is not an endorsement.